These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 11779085)

  • 1. Integrins as targets of angiogenesis inhibition.
    Westlin WF
    Cancer J; 2001; 7 Suppl 3():S139-43. PubMed ID: 11779085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha(v)beta3 and alpha(v)beta5 integrin receptor antagonist.
    Kumar CC; Malkowski M; Yin Z; Tanghetti E; Yaremko B; Nechuta T; Varner J; Liu M; Smith EM; Neustadt B; Presta M; Armstrong L
    Cancer Res; 2001 Mar; 61(5):2232-8. PubMed ID: 11280792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrins alpha(v)beta3 and alpha(v)beta5 are expressed by endothelium of high-risk neuroblastoma and their inhibition is associated with increased endogenous ceramide.
    Erdreich-Epstein A; Shimada H; Groshen S; Liu M; Metelitsa LS; Kim KS; Stins MF; Seeger RC; Durden DL
    Cancer Res; 2000 Feb; 60(3):712-21. PubMed ID: 10676658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A peptidomimetic antagonist of the integrin alpha(v)beta3 inhibits Leydig cell tumor growth and the development of hypercalcemia of malignancy.
    Carron CP; Meyer DM; Pegg JA; Engleman VW; Nickols MA; Settle SL; Westlin WF; Ruminski PG; Nickols GA
    Cancer Res; 1998 May; 58(9):1930-5. PubMed ID: 9581835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics.
    Haubner R; Wester HJ; Burkhart F; Senekowitsch-Schmidtke R; Weber W; Goodman SL; Kessler H; Schwaiger M
    J Nucl Med; 2001 Feb; 42(2):326-36. PubMed ID: 11216533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological and molecular properties of a new alpha(v)beta3/alpha(v)beta5 integrin antagonist.
    Belvisi L; Riccioni T; Marcellini M; Vesci L; Chiarucci I; Efrati D; Potenza D; Scolastico C; Manzoni L; Lombardo K; Stasi MA; Orlandi A; Ciucci A; Nico B; Ribatti D; Giannini G; Presta M; Carminati P; Pisano C
    Mol Cancer Ther; 2005 Nov; 4(11):1670-80. PubMed ID: 16275988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SB-267268, a nonpeptidic antagonist of alpha(v)beta3 and alpha(v)beta5 integrins, reduces angiogenesis and VEGF expression in a mouse model of retinopathy of prematurity.
    Wilkinson-Berka JL; Jones D; Taylor G; Jaworski K; Kelly DJ; Ludbrook SB; Willette RN; Kumar S; Gilbert RE
    Invest Ophthalmol Vis Sci; 2006 Apr; 47(4):1600-5. PubMed ID: 16565398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blockade of alpha v beta3 and alpha v beta5 integrins by RGD mimetics induces anoikis and not integrin-mediated death in human endothelial cells.
    Maubant S; Saint-Dizier D; Boutillon M; Perron-Sierra F; Casara PJ; Hickman JA; Tucker GC; Van Obberghen-Schilling E
    Blood; 2006 Nov; 108(9):3035-44. PubMed ID: 16835373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone sialoprotein supports breast cancer cell adhesion proliferation and migration through differential usage of the alpha(v)beta3 and alpha(v)beta5 integrins.
    Sung V; Stubbs JT; Fisher L; Aaron AD; Thompson EW
    J Cell Physiol; 1998 Sep; 176(3):482-94. PubMed ID: 9699501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contortrostatin, a homodimeric snake venom disintegrin, is a potent inhibitor of osteoclast attachment.
    Mercer B; Markland F; Minkin C
    J Bone Miner Res; 1998 Mar; 13(3):409-14. PubMed ID: 9525341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disruption of matrix metalloproteinase 2 binding to integrin alpha vbeta 3 by an organic molecule inhibits angiogenesis and tumor growth in vivo.
    Silletti S; Kessler T; Goldberg J; Boger DL; Cheresh DA
    Proc Natl Acad Sci U S A; 2001 Jan; 98(1):119-24. PubMed ID: 11134507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alpha(v)beta3 and alpha(v)beta5 integrin expression in meningiomas.
    Bello L; Zhang J; Nikas DC; Strasser JF; Villani RM; Cheresh DA; Carroll RS; Black PM
    Neurosurgery; 2000 Nov; 47(5):1185-95. PubMed ID: 11063113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated 90Y-labeled nanoparticles.
    Li L; Wartchow CA; Danthi SN; Shen Z; Dechene N; Pease J; Choi HS; Doede T; Chu P; Ning S; Lee DY; Bednarski MD; Knox SJ
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1215-27. PubMed ID: 15001266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studies on the expression of alpha(v)beta3 integrin receptors in non-malignant and malignant human cervical tumor tissues.
    Chattopadhyay N; Chatterjee A
    J Exp Clin Cancer Res; 2001 Jun; 20(2):269-75. PubMed ID: 11484986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alpha-V/beta-3 and alpha-V/beta-5 integrin distribution in neoplastic kidney.
    Rabb H; Barroso-Vicens E; Adams R; Pow-Sang J; Ramirez G
    Am J Nephrol; 1996; 16(5):402-8. PubMed ID: 8886177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrin function in osteoclasts.
    Rodan SB; Rodan GA
    J Endocrinol; 1997 Sep; 154 Suppl():S47-56. PubMed ID: 9379137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alpha v integrins as receptors for tumor targeting by circulating ligands.
    Pasqualini R; Koivunen E; Ruoslahti E
    Nat Biotechnol; 1997 Jun; 15(6):542-6. PubMed ID: 9181576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography.
    Haubner R; Wester HJ; Weber WA; Mang C; Ziegler SI; Goodman SL; Senekowitsch-Schmidtke R; Kessler H; Schwaiger M
    Cancer Res; 2001 Mar; 61(5):1781-5. PubMed ID: 11280722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel disintegrin salmosin inhibits tumor angiogenesis.
    Kang IC; Lee YD; Kim DS
    Cancer Res; 1999 Aug; 59(15):3754-60. PubMed ID: 10446992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting integrins alpha v beta 3 and alpha v beta 5 for blocking tumor-induced angiogenesis.
    Kumar CC; Armstrong L; Yin Z; Malkowski M; Maxwell E; Ling H; Yaremko B; Liu M; Varner J; Smith EM; Neustadt B; Nechuta T
    Adv Exp Med Biol; 2000; 476():169-80. PubMed ID: 10949664
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.